David J. Taylor
Trade Performance Intelligence
Score: 6/10Performance calculated from trade date to most recent market close. Real-time stock data from Financial Modeling Prep. This is not financial advice.
Stock Price at Trade vs. Today
Real market data showing how each stock moved since the congress member traded it.
Suspicious Timing Detected
5 flagsRep. Taylor bought $1,001 - $15,000 in $V (Visa Inc.) on 2025-12-03 — 1 day before the HUSTLE Act (S3378) was introduced, which proposes tax-exempt NIL investment accounts that could expand the market for financial services.
Rep. Taylor sold $1,001 - $15,000 in $AMGN (Amgen Inc. - Common Stock) on 2025-12-03 — 2 days before the 'Skinny Labels, Big Savings Act' (HR6485) was introduced, aiming to reduce patent infringement risk for generic drug manufacturers.
Rep. Taylor sold $1,001 - $15,000 in $AMGN (Amgen Inc. - Common Stock) on 2025-12-03 — 69 days before the 'Break Up Big Medicine Act' (S3822) was introduced, which aims to prohibit common ownership between pharmaceutical companies.
Rep. Taylor bought $1,001 - $15,000 in $V (Visa Inc.) on 2025-12-03 — 70 days before the Financial Stability Oversight Council Improvement Act of 2025 was introduced, which introduces a new procedural step for designating nonbank financial institutions.
These flags identify timing coincidences between stock trades and legislative activity. They do not imply wrongdoing. Click any bill number or ticker to see the full analysis.
Share This Filing
All Transactions
Connected Legislative Activity
10 signalsThese bills and contracts share tickers or sectors with this filing's trades.
Financial Stability Oversight Council Improvement Act of 2025
The Financial Stability Oversight Council Improvement Act of 2025, currently in the House, introduces a new procedural step for designating nonbank financial companies as systemically important, potentially reducing future regulatory burdens. This bill directly benefits large nonbank financial firms by requiring the Financial Stability Oversight Council (FSOC) to consider alternative actions before imposing Federal Reserve supervision. Companies like Berkshire Hathaway, Blackstone, PayPal, Visa, and Mastercard are positioned to benefit from this reduced regulatory risk.
GAP Supply Act
The GAP Supply Act (HR7528) was introduced on February 12, 2026, and referred to the House Committee on Energy and Commerce. This bill aims to allow outsourcing facilities to continue supplying drugs during shortages for an additional 180 days, providing regulatory stability for pharmaceutical supply chains. The bill is in an early legislative stage.
Break Up Big Medicine Act
The 'Break Up Big Medicine Act' (S.3822), introduced by Senator Warren and cosponsored by Senator Hawley, aims to prohibit common ownership between pharmacy benefit managers, insurers, drug/medical device wholesalers, and certain medical service providers. This bill, currently in the early stages of being referred to the Committee on the Judiciary, targets the vertical integration prevalent in the healthcare sector, potentially forcing divestitures for large pharmaceutical and healthcare conglomerates. While the bill does not specify direct funding, its provisions could significantly restructure the healthcare market.
Combatting Money Laundering in Cyber Crime Act of 2025
The Combatting Money Laundering in Cyber Crime Act of 2025 (HR5877) has been reported out of committee, expanding Secret Service authority and FinCEN reporting, which could increase demand for blockchain analytics and fraud detection. Digital asset-related companies like $COIN, $RIOT, $MARA, and $BKKT have seen positive movement over the last 7 days, despite 30-day declines. Financial technology companies such as $PYPL, $V, and $MA have also shown positive 7-day changes.
Skinny Labels, Big Savings Act
The 'Skinny Labels, Big Savings Act' (HR6485) aims to reduce patent infringement risk for generic drug manufacturers by providing a statutory safe harbor, directly reversing the GlaxoSmithKline LLC v. Teva Pharmaceuticals USA, Inc. precedent. This bill, currently in the early stages of the legislative process, would increase market access for generics and biosimilars, benefiting companies like Teva Pharmaceutical Industries Limited ($TEVA) and Viatris Inc. ($VTRS), while potentially increasing competition for innovator drug companies such as Amgen Inc. ($AMGN), Pfizer Inc. ($PFE), Johnson & Johnson ($JNJ), and Merck & Co., Inc. ($MRK).
Pensions for All Act
The Pensions for All Act (HR7556) mandates employer-provided retirement plans, which would significantly expand the addressable market for financial services and fintech companies. The bill is in the early stages of the legislative process, having been introduced and referred to three House committees on February 12, 2026, with a companion bill (S2335) in the Senate. While the bill creates a new revenue stream for asset managers and payment processors, its current early stage means immediate market impact is limited.
Bringing the Discount Window into the 21st Century Act
HR3390, the 'Bringing the Discount Window into the 21st Century Act,' mandates a Federal Reserve review of its discount window operations, focusing on technology and efficiency. While the bill does not appropriate funds, it directs the Federal Reserve to develop a remediation plan for identified deficiencies, which could lead to future technology infrastructure upgrades benefiting financial technology providers. The bill is currently in the House, having been reported by the Committee on Financial Services.
PROTECT Taiwan Act
The PROTECT Taiwan Act (HR1531) has been reported by the House Financial Services Committee, indicating legislative progress for a bill that mandates U.S. action to exclude China from international financial organizations if China threatens Taiwan. This bill introduces geopolitical risk for global financial institutions and uncertainty for technology firms reliant on cross-border financial flows. Financial stocks like Citigroup ($C) and Goldman Sachs ($GS) have shown strong 7-day gains of +9.41% and +7.24% respectively, while payment processors PayPal ($PYPL), Visa ($V), and Mastercard ($MA) have seen more modest 7-day gains but negative 30-day changes.
HUSTLE Act
The HUSTLE Act, S.3378, proposes tax-exempt NIL investment accounts, which could expand the addressable market for financial services and payment processors. The bill is in the early stages, having been referred to the Committee on Finance on December 4, 2025. Current market data shows mixed performance among financial institutions and payment processors over the past 7 and 30 days.
Community Bank Relief Act
The 'Community Bank Relief Act' (HR7484) proposes annual inflation adjustments to payment card transaction fee thresholds, formalizing existing economic realities. The bill is in early stages, having been referred to the House Committee on Financial Services. Recent market data shows mixed performance among payment processors and card networks, with Visa ($V) and Mastercard ($MA) showing slight 7-day gains, while Fidelity National Information Services ($FIS) and Global Payments Inc. ($GPN) experienced declines.
Live Charts
Other Filings by David J. Taylor
Data sourced from the U.S. House of Representatives Office of the Clerk Financial Disclosure system. Stock prices from Financial Modeling Prep. Suspicious timing flags identify coincidences between stock trades and legislative activity and do not imply any wrongdoing or illegal activity. This is not financial advice.